HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) rose more than 6% in the morning session. RenBiologics' business has entered the commercialization realization phase.

Biocytogen Pharmaceuticals-B (02315) rose more than 6% in early trading. As of the time of publication, it has risen by 6.03% to 50.85 Hong Kong dollars, with a turnover of 42.8952 million Hong Kong dollars. On the news front, Biocytogen Pharmaceuticals previously participated in the AACR annual meeting, showcasing 36 latest research results in poster form, covering various forms of drugs including fully human monoclonal antibodies, bispecific/multispecific antibodies, monoclonal antibodies and bispecific antibody conjugates, nanobodies, TCR molecules, as well as progress in 12 preclinical animal models and pharmacological studies. This fully demonstrates the latest developments and synergies of the two major platforms "Thousand Mice Thousand Antibodies" and "Biocytogen Animals." China Securities Co., Ltd. released a research report stating that the company's BioMice business is benefiting from the increasing demand for humanized target mice, expansion of MNC clients, and improvement in overseas service capabilities, with revenue expected to maintain rapid growth. The RenBiologics business has entered a period of commercial realization, with potential long-term growth sources including antibody molecule transfer, platform authorization, milestone payments, and potential sales royalties.